Pemetrexed and bevacizumab‑containing chemotherapy for pleomorphic carcinoma of the lung

Tamura,Tomohiro; Ohara,Gen; Kagohashi,Katsunori; Kawaguchi,Mio; Kurishima,Koichi; Satoh,Hiroaki

doi:10.3892/mco.2016.758

Pemetrexed and bevacizumab‑containing chemotherapy for pleomorphic carcinoma of the lung

Authors:
- Tomohiro Tamura
- Gen Ohara
- Katsunori Kagohashi
- Mio Kawaguchi
- Koichi Kurishima
- Hiroaki Satoh
View Affiliations

Affiliations: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan, Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8575, Japan, Division of Respiratory Medicine, Tsukuba Medical Center, Tsukuba, Ibaraki 305‑8558, Japan
Published online on: January 29, 2016 https://doi.org/10.3892/mco.2016.758
Pages: 616-618

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pleomorphic carcinoma of the lung is a rare, highly malignant subtype of lung cancer, with a more aggressive clinical course compared with other types of non‑small‑cell lung cancer (NSCLC). Pemetrexed and bevacizumab are currently evaluated as two of the most reliable chemotherapeutic drugs for advanced NSCLC. We herein report a case of a 68‑ and a 46‑year‑old man with recurrent and chemo‑naïve pleomorphic carcinoma of the lung, respectively, who were treated with a combination of carboplatin, pemetrexed and bevacizumab. The overall survival after the initiation of chemotherapy was 30 and 8 months, respectively. These cases exhibited a relatively long‑term survival with chemotherapy. In the absence of definitive clinical trials, which are unlikely to be performed due to the rarity of this tumor, our cases demonstrated the potential utility of pemetrexed- and bevacizumab‑containing chemotherapy. Our results also suggested that pemetrexed‑containing chemotherapy may be key to the treatment of pleomorphic carcinoma of the lung.

View Figures

View References

1	Chang YL, Lee YC, Shih JY and Wu CT: Pulmonary pleomorphic (spindle) cell carcinoma: Peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma. Lung Cancer. 34:91–97. 2001. View Article : Google Scholar : PubMed/NCBI
2	Ito K, Oizumi S, Fukumoto S, Harada M, Ishida T, Fujita Y, Harada T, Kojima T, Yokouchi H and Nishimura M: Hokkaido Lung Cancer Clinical Study Group: Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer. 68:204–210. 2010. View Article : Google Scholar : PubMed/NCBI
3	Pelosi G, Sonzogni A, De Pas T, Galetta D, Veronesi G, Spaggiari L, Manzotti M, Fumagalli C, Bresaola E, Nappi O, et al: Review article: Pulmonary sarcomatoid carcinomas: A practical overview. Int J Surg Pathol. 18:103–120. 2010. View Article : Google Scholar : PubMed/NCBI
4	Mochizuki T, Ishii G, Nagai K, Yoshida J, Nishimura M, Mizuno T, Yokose T, Suzuki K and Ochiai A: Pleomorphic carcinoma of the lung: Clinicopathological characteristics of 70 cases. Am J Surg Pathol. 32:1727–1735. 2008. View Article : Google Scholar : PubMed/NCBI
5	Fishback NF, Travis WD, Moran CA, Guinee DG Jr, McCarthy WF and Koss MN: Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer. 73:2936–2945. 1994. View Article : Google Scholar : PubMed/NCBI
6	Rossi G, Cavazza A, Sturn N, Migaldi M, Facciolongo N, Longo L, Maiorana A and Brambilla E: Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: A clinicopathlogic and immunohistochemical study of 75 cases. Am J Surg Pathol. 27:311–324. 2003. View Article : Google Scholar : PubMed/NCBI
7	Yamamoto S, Hamatake D, Ueno T, Higuchi T, Hiratsuka M, Shiraishi T, Iwasaki A and Shirakusa T: Clinicopathological investigation of pulmonary pleomorphic carcinoma. Eur J Cardiothorac Surg. 32:873–876. 2007. View Article : Google Scholar : PubMed/NCBI
8	Bae HM, Min HS, Lee SH, Kim DW, Chung DH, Lee JS, Kim YW and Heo DS: Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer. 58:112–115. 2007. View Article : Google Scholar : PubMed/NCBI
9	Raveglia F, Mezzetti M, Panigalli T, Furia S, Giuliani L, Conforti S and Meda S: Personal experience in surgical management of pulmonary pleomorphic carcinoma. Ann Thorac Surg. 78:1742–1747. 2004. View Article : Google Scholar : PubMed/NCBI
10	Fuld AD, Dragnev KH and Rigas JR: Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother. 11:1387–1402. 2010. View Article : Google Scholar : PubMed/NCBI
11	Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH and Ahn MJ: The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma. Med Oncol. 26:287–291. 2009. View Article : Google Scholar : PubMed/NCBI
12	Chen Y, Wen Q, Liu H, Ao R, Wu X, Guo L, Wang W, He C and Wang J: Pemetrexed versus vinorelbine treatment of advanced non-squamous non-small cell lung cancer in elderly patients. Mol Clin Oncol. 1:553–557. 2013.PubMed/NCBI
13	Shijubo N, Inoue Y, Hirasawa M, Igarashi T, Mori M, Matsuura A, Uede T and Suzuki A: Granulocyte colony-stimulating factor-producing large cell undifferentiated carcinoma of the lung. Intern Med. 31:277–280. 1992. View Article : Google Scholar : PubMed/NCBI
14	Yamamoto M, Manabe S, Moriyama Y, Ishii H, Tanaka S, Takahashi R, Tomaru K, Kobayashi N, Kudo M, Sasaki M, et al: Long-term remission achieved via combined chemotherapy and radiotherapy in a non-resectable granulocyte colony-stimulating factor producing pleomorphic carcinoma of the lung. Intern Med. 52:2259–2263. 2013. View Article : Google Scholar : PubMed/NCBI
15	Mao L: Recent advances in the molecular diagnosis of lung cancer. Oncogene. 21:6960–6969. 2002. View Article : Google Scholar : PubMed/NCBI